Antiviral Drugs

Antiviral drugs represent a diverse array of pharmaceutical agents essential in the relentless battle against viral infections. Nucleotide analogs like remdesivir demonstrate efficacy against a spectrum of RNA viruses, including the formidable SARS-CoV-2, by inhibiting viral RNA synthesis. Protease inhibitors, such as lopinavir and darunavir, play a crucial role in managing retroviral infections by disrupting viral protein maturation. Entry inhibitors, exemplified by enfuvirtide and maraviroc, prevent viral entry into host cells, contributing to the multifaceted defense against viral invasion. Immunomodulators like interferons bolster the host's innate immune response, aiding in the identification and elimination of virus-infected cells. The advent of CRISPR-based technologies and RNA interference (RNAi) showcases the potential for precise targeting of viral genetic material. Ongoing research focuses on developing broad-spectrum antivirals, innovative delivery mechanisms, and alternative therapeutic approaches to address the evolving challenges posed by viral infections. The pursuit of effective antiviral strategies remains pivotal in safeguarding public health against emerging and existing viral threats.